Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
Pfizer
University of Nebraska
Northwestern University
Barbara Ann Karmanos Cancer Institute
Fred Hutchinson Cancer Center
Medical University of Vienna